u/ShaveMyPineapple

Compass Pathways is developing psychedelic therapy for treatment-resistant depression. Commenter (MD/PhD) claims it may lead a paradigm shift. Small-cap biotech with a novel, high-potential pipeline; if FDA approval path clears, significant upside. A speculative early-stage biotech bet on a new treatment class; high risk/reward. Regulatory rejection, clinical trial failures, competitive landscape (e.g., MAPS), capital dilution.

INTR (Inter & Co) has forward P/E of 8, 5-year EPS growth estimate of +25%, PEG ~0.3, ROE 15% and increasing, insiders own 45%. These metrics suggest deep undervaluation relative to growth, while large insider ownership aligns management with shareholders. Recent sell-off in LatAm/financials creates a buying opportunity. A small-cap value play with strong fundamentals and insider alignment; potential for violent rebounds as seen historically. Continued weakness in Latin American markets; currency and political risk in Brazil; possible earnings miss or sector headwinds.